Management of Hepatocellular CAncer in the time of SARS-CoV-2
File(s)
Accepted version
Author(s)
Sharma, Rohini
Pinato, David J
Type
Journal Article
Abstract
As COVID-19 the disease caused by SARS-CoV-2 continues to have a profound impact on global health, there have been a number of guidelines recently published addressing the management of patients with liver disease during the COVID-19 pandemic including the recently published EASL-ESCMID Position Paper, guidelines issued by the International Liver Cancer Association and the American Association for the Study of Liver Diseases (1-3). All publications present a sound discussion regarding the challenges face by both patients and clinicians alike in the management of chronic liver disease in the setting of this ongoing pandemic.
Date Issued
2020-08-01
Date Acceptance
2020-05-01
Citation
Liver International, 2020, 40 (8), pp.1823-1825
ISSN
1478-3223
Publisher
Wiley
Start Page
1823
End Page
1825
Journal / Book Title
Liver International
Volume
40
Issue
8
Copyright Statement
This article is protected by copyright. All rights reserved. This is the accepted version of the following article: Sharma, R. and Pinato, D.J. (2020), Management of Hepatocellular Cancer in the time of SARS‐CoV‐2. Liver Int. Accepted Author Manuscript, which has been published in final form at https://doi.org/10.1111/liv.14517
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/32416633
Subjects
COVID-19
TACE
ablation
hepatocellular carcinoma
surgery
tyrosine kinase Inhibitors
Publication Status
Published
Coverage Spatial
United States
Date Publish Online
2020-05-16